-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Fidanacogene Elaparvovec-dzkt for Treatment of Adults with Moderate to Severe Hemophilia B

Program: Special-Interest Sessions
Session: ASH-FDA Joint Symposium II: Challenges and Innovations in Rare Diseases in Non-Malignant Hematology
Hematology Disease Topics & Pathways:
Education
Monday, December 9, 2024, 4:30 PM-6:00 PM

Megha Kaushal, MD, MSc

Division of Clinical Evaluation Hematology, Office of Therapeutic Products (OTP), Center for Biologics Evaluation and Research (CBER), US Food and Drug Administration, Silver Spring, MD

Disclosures: No relevant conflicts of interest to declare.

See more of: ASH-FDA Joint Symposium II: Challenges and Innovations in Rare Diseases in Non-Malignant Hematology
See more of: Special-Interest Sessions
<< Previous Presentation | Next Presentation >>